一、主要研究方向
肿瘤耐药的机制及相关药物研发
二、个人简历
省级教学名师、安徽省药理学会副秘书长兼常务理事，获省级教学成果一等奖1项，二等奖3项
2015.07～至今 蚌埠医学院药理学教研室，教授
2012.07～2013.07 美国罗格斯大学医学院，访问学者
2010.07～2015.07 蚌埠医学院药理学教研室，副教授
2005.07～2010.07 蚌埠医学院药理学教研室，讲师
2000.07～2005.07 蚌埠医学院药理学教研室，助教
三、主持科研/教学项目
1. 国家自然科学基金青年科学基金项目，编号：81001457，项目名称：睾丸细胞中缝隙链接蛋白的表达及其对铂类抗肿瘤药物作用的靶向影响，2011.1-2013.12，20万元，主持；
2. 安徽省自然科学基金，编号：2008085MH275，项目名称：Pannexin通道蛋白在耐铂类睾丸癌细胞自噬异常中的作用及分子机制，2020.7-2022.6，10万元，主持；
3.安徽省高校优秀青年人才支持计划重点项目，编号：gxyqZD2016158，项目名称：以多靶点调控连接蛋白功能为策略的铂类化合物耐药性逆转药物筛选及研发，2016.1-2018.12，6万元，主持；
4. 安徽省教育厅自然科学研究重点项目，编号：KJ2015A180，项目名称：睾丸癌细胞连接蛋白Cx43及Px-1在铂类化合物耐药性中的作用及其调控机制，2015.1-2016.12，5万元，主持；
5. 安徽省教育厅自然科学研究重点项目，编号：2025AHGXZK31181，项目名称：缝隙连接蛋白Cx43促进的铁死亡在睾丸癌耐顺铂中的作用及机制，2026.1-2027.12，20万元，主持。
四、代表性成果（论文/专利/专著等）
1. Hongyu Li,Boying Wang,Sheng Wu,Shuying Dong,Guojun Jiang,Yingying Huang,Xuhui Tong*,Meiling Yu*.Ferroptosis is involved in polymyxin B-induced acute kidney injury via activation of p53[J].Chem Biol Interact.2023 Jun 1:378:110479.doi:10.1016/j.cbi.2023.110479.
2. Min Yuan,Yanxue Yao,Dandan Wu,Chenlu Zhu,Shuying Dong,Xuhui Tong*.Pannexin1 inhibits autophagy of cisplatin-resistant testicular cancer cells by mediating ATP release[J].2022,21(15):1651-1661.
Anticancer Drugs
3. Guojun Jiang,Yaming Liu,Ru Wang,Meiling Yu,Yuelin Zhang,Shuying Dong,Hao Liu,Xuhui Tong*Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells[J].Anticancer Drugs,2020 Feb;31(2):123-130.
4. Liu H,Yuan M,Yao Y,Wu D,Dong S,Tong X(*).In vitro effect of Pannexin 1 channel on the invasion and migration of I-10 testicular cancer cells via ERK1/2 signaling pathway[J].biomed Pharmacother.2019 Jun 12;117:109090.
5. Wu D,Li B,Liu H,Yuan M,Yu M,Tao L,Dong S,Tong X(*).In vitro inhibited effect of gap junction composed of Cx43 in the invasion and metastasis of testicular cancer resistanced to cisplatin[J].Biomed Pharmacother.2018;98:826-833.
6. Yu, Meiling; Zou,Qi; Wu, Xiaoxiang; Han, Guangshu; Tong, Xuhui(*). Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway [J]. Biomed Pharmacother, 2017, 11, 95:1844~1852.
7. Wu, Dandan; Wu, Jianfeng; Liu, Haofeng; Yu, Meiling; Tao, Liang; Dong, Shuying; Tong, Xuhui(*). Role of Pannexin1 channels in the resistance of I-10 testicular cancer cells to cisplatin mediated by ATP/IP3 pathway [J]. Biomed Pharmacother, 2017.10, 94: 514~522.
8. Jiang, Guojun; Dong, Shuying; Yu, Meiling; Han, Xi; Zheng, Chao; Zhu, Xiaoguang; Tong, Xuhui(*), Influence of gap junction intercellular communication composed of connexin 43 on the antineoplastic effect of adriamycin in breast cancer cells [J]. Oncol Lett, 2017.2, 13(2): 857~866
9. Wu, Jian-Feng; Ji, Jie; Dong, Shu-Ying; Li, Bei-Bei; Yu, Mei-Ling; Wu, Dan-Dan; Tao, Liang; Tong, Xu-Hui(*). Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function [J]. Oncol Rep, 2016.12, 36(6): 3251~3258
10. Tong X(#), Lopez W(#), Ramachandran J, Ayad WA, Liu Y, Lopez-Rodriguez A, Harris AL, Contreras JE(*). Glutathione release through connexin hemichannels:Implications for chemical modification of pores permeable to large molecules [J]. J Gen Physiol. 2015，146(3): 245-54.
